2,3,4,5-四氢-1,5-苯并噻氮杂卓 | 40358-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 中文名称: 2,3,4,5-四氢-1,5-苯并噻氮杂卓
• 英文名称: 2,3,4,5-tetrahydro-benzo[b][1,4]thiazepine
• 英文别名: 2.3.4.5-Tetrahydro-1.5-benzthiazepin；2,3,4,5-Tetrahydro-1,5-benzothiazepin；2,3,4,5-Tetrahydro-1,5-benzothiazepine
• CAS: 40358-33-6
• 化学式: C₉H₁₁NS
• mdl: MFCD06364981
• 分子量: 165.259
• InChiKey: XSLBWZNMWUEVMS-UHFFFAOYSA-N

物化性质

• 沸点：
  117-120 °C(Press: 0.9 Torr)
• 密度：
  1.1737 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2,3,4,5-四氢-1,5-苯并噻氮杂卓 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 2,3,4,5-Tetrahydro-1,5-benzothiazepin hydrochloride
  参考文献：
  名称：

  二异丁基氢化铝通过还原扩环法选择性合成芳族杂环氮杂环化合物及其反应机理的研究

  摘要：

  描述了与二异丁基氢化铝（DIBALH）稠合到芳环上的环状酮肟的还原扩环反应的系统研究。该反应区域选择性地提供了多种五至八元双环杂环或三环杂环，其包含与芳香环相邻的氮，包括二氢吲哚，1,2,3,4,5,6-六氢苯并[ b ]偶氮辛，3,4-二氢-2 H-苯并[ b ] [1,4]恶嗪，2,3,4,5-四氢苯并[ b ] [1,4]噻氮平，1,2,3,4,5,6-六氢氮庚啶[3 ，2- b ]吲哚，2,3,4,5-四氢-1 H-苯并噻吩并[2,3- b ]氮杂，2,3,4,5-四氢-1 H-苯并噻吩并[3,2- b]氮杂，5,6-二氢菲啶和5,6,11,12-四氢二苯并[ b，f ]偶氮星。基于受限的Becke三参数加Lee-Yang-Parr（B3LYP）密度泛函理论（DFT）和6-31G（d）基础集，研究了导致重排的反应机理。发现该反应通过逐步机理通过三中心过渡态进行，因为沿着本征反应坐标

  DOI：

  10.1021/jo902177p
• 作为产物：
  描述：

  1-茚酮肟 在 二异丁基氢化铝 、 sodium fluoride 作用下， 以 正己烷 、 二氯甲烷 、 水 为溶剂， 反应 2.75h， 以71%的产率得到2,3,4,5-四氢-1,5-苯并噻氮杂卓
  参考文献：
  名称：

  Regiospecific Synthesis of Unsubstituted Basic Skeletons of Heterocycles Containing Nitrogen Neighboring an Aromatic Ring by the Reductive Ring Expansion Reaction Using Diisobutylaluminum Hydride

  摘要：

  A systematic investigation of reductive ring expansion reaction of oximes with diisobutylaluminum hydride (DIBAH) was performed. The reaction regiospecifically provided a variety of unsubstituted bicyclic heterocycles 3a-3g or tricyclic heterocycles 3h, 3j-3i that contained nitrogen attached to an aromatic ring.

  DOI：

  10.3987/com-08-11629

文献信息

• [EN] BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA<br/>[FR] DERIVES D'ACIDE BENZOIQUE UTILISES EN TANT QUE MODULATEURS DE PPAR ALPHA AND GAMMA
  申请人：ASTRAZENECA AB

  公开号：WO2004000295A1

  公开（公告）日：2003-12-31

  A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group -(CH2)m-T-(CH2)n-U-(CH2)p- is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH2)2, O(CH2)3, NC(O)NR4(CH2)2 , CH2S(O2)NR5(CH2)2, CH2N(R6)C(O)CH2, (CH2)2N(R6)C(O)(CH2)2 , C(O)NR7 CH2 , C(O)NR7(CH2 )2 , and CH2N(R6)C(O)CH2O; V represents O, S, NR8, or a single bond;q represents 1, 2 or 3 ; W represents O, S, N(R9)C(O) , NR10,or a single bond;R2 represents halo, a C 1-4 alkyl group which is optionally substituted by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, CN or NO2 ; r represents 0, 1, 2 or 3 ; R3 represents halo, a C 1-4 alkyl group which is optionally substituted by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, or CN ; s represents 0, 1, 2 or 3 ; and R4, R5, R6 , R7, R8 , R9 and R10 independently represent H, a C 1-10 alkyl group, aryl or an aryl C 1-4 alkyl group or when m is 0 and T represents a group N(R6)C(O) or a group (R5)NS(O2) then R1 and R6 or R1 and R5 together with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

  式（I）的化合物，其中R1代表芳基，可选地被杂环基取代，或者被芳基取代的杂环基，其中每个芳基或杂环基可选地被取代；在苯环中的3位或4位之一连接有组-(CH2)m-T-(CH2)n-U-(CH2)p-，如式（I）中的数字所示，并表示从以下一个或多个中选择的组：O(CH2)2，O(CH2)3，NC(O)NR4(CH2)2，CH2S(O2)NR5(CH2)2，CH2N(R6)C(O)CH2，(CH2)2N(R6)C(O)(CH2)2，C(O)NR7CH2，C(O)NR7(CH2)2和CH2N(R6)C(O)CH2O；V代表O，S，NR8或单键；q代表1、2或3；W代表O，S，N(R9)C(O)，NR10或单键；R2代表卤素，可选地被一个或多个氟取代的C1-4烷基，可选地被一个或多个氟取代的C1-4烷氧基，C1-4酰基，芳基，芳基C1-4烷基，CN或NO2；r代表0、1、2或3；R3代表卤素，可选地被一个或多个氟取代的C1-4烷基，可选地被一个或多个氟取代的C1-4烷氧基，C1-4酰基，芳基，芳基C1-4烷基或CN；s代表0、1、2或3；R4、R5、R6、R7、R8、R9和R10独立地代表H，C1-10烷基，芳基或芳基C1-4烷基，或者当m为0且T代表N(R6)C(O)或(R5)NS(O2)时，R1和R6或R1和R5与它们连接的氮原子一起代表杂芳基；以及其药学上可接受的盐，制备这种化合物的方法，它们在治疗与胰岛素抵抗相关的临床病症中的用途，它们的治疗用途的方法和含有它们的药物组合物。
• [EN] COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE1
  申请人：ALLGENESIS BIOTHERAPEUTICS INC

  公开号：WO2016172255A1

  公开（公告）日：2016-10-27

  The present invention relates to compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, Y, Z, Q, W, m, u, ring (A), R2, R3, R4, R5 and R6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of Formula (I) and a therapeutic method of treating and/or preventing Downs syndrome, β-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, Alzheimer's disease and/or Down syndrome, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases (stroke).

  本发明涉及式（I）的化合物或其立体异构体、互变异构体、或其药学上可接受的盐或溶剂，其中X、Y、Z、Q、W、m、u、环（A）、R2、R3、R4、R5和R6如规范和权利要求中所定义。本发明提供了含有式（I）化合物的药物组合物，以及治疗和/或预防唐氏综合征、β-淀粉样血管病、与认知损伤相关的疾病、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、神经退行性疾病、早老性痴呆、老年性痴呆和与帕金森病、阿尔茨海默病和/或唐氏综合征相关的痴呆、年龄相关性黄斑变性（AMD）、青光眼、嗅觉功能障碍、创伤性脑损伤、进行性肌肉疾病、2型糖尿病和心血管疾病（中风）的治疗方法。
• [EN] HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS<br/>[FR] COMPOSES CONDENSES HETEROCYCLIQUES UTILISES EN TANT QU'ANTIDIURETIQUES
  申请人：FERRING BV

  公开号：WO2006018443A1

  公开（公告）日：2006-02-23

  The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

  这项发明涉及通式1中的化合物，其中G1是胺基。根据该发明的化合物是抗利尿激素V2受体激动剂。这些化合物的药物组合物可用作抗利尿剂。
• Palladium-Catalyzed Intramolecular CH Difluoroalkylation: Synthesis of Substituted 3,3-Difluoro-2-oxindoles
  作者：Shi-Liang Shi、Stephen L. Buchwald

  DOI：10.1002/anie.201410471

  日期：2015.1.26

  3‐difluoro‐2‐oxindoles through a robust and efficient palladium‐catalyzed CH difluoroalkylation is described. This process generates a broad range of difluorooxindoles from readily prepared starting materials. The use of BrettPhos as the ligand was crucial for high efficiency. Preliminary mechanistic studies suggest that oxidative addition is the rate‐determining step for this process.

  描述了通过稳健而有效的钯催化的CH二氟烷基化反应合成3,3-二氟-2-氧吲哚的方法。该方法从容易制备的起始原料中产生了广泛范围的二氟羟吲哚。使用BrettPhos作为配体对于提高效率至关重要。初步的机理研究表明，氧化添加是该过程的决定速率的步骤。
• Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 1: Identification and structure–activity relationships
  作者：He Zhao、Andrew Thurkauf、Xiaoshu He、Kevin Hodgetts、Xiaoyan Zhang、Stanislaw Rachwal、Renata X. Kover、Alan Hutchison、John Peterson、Andrzej Kieltyka、Robbin Brodbeck、Renee Primus、Jan W.F. Wasley

  DOI：10.1016/s0960-894x(02)00655-8

  日期：2002.11

  Optimization of the lead compound 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2,3-dihydro-indol-1-yl)-ethanone 1 by systematic structure-activity relation (SAR) studies lead to two potent compounds 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)-ethanone 2n and 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)-ethanone 7b. Their related synthesis was

  通过系统结构-活性关系最优化铅化合物2-[-4-（4-氯苄基）-哌嗪-1-基] -1-（2,3-二氢-吲哚-1-基）-乙酮1 （SAR）研究产生了两种有效的化合物2-[-4-（4-氯-苄基）-哌嗪-1-基] -1-（2-甲基-2,3-二氢-吲哚-1-基）-乙酮2n和2-[-4-（4-氯苄基）-哌嗪-1-基] -1-（2-甲基-2,3-二氢-吲哚-1-基）-乙酮7b。还报道了它们的相关合成。